Overall we are willing to remain patient with CVS’s stock to see their new strategy being implemented. This could help change the complex healthcare landscape in the US.
We also see limited downside risk at this point, with the stock trading at 11.2x next year’s P/E, and offering a 2.8% dividend yield. Continue reading “CVS/Aetna Talking Points”
Skip to content